Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
February 16, 2022 09:40 ET
|
Hillstream BioPharma Inc.
-Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates ferroptosis, an emerging iron-mediated cell...